These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19758115)

  • 1. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors.
    Toms TE; Symmons DP; Kitas GD
    Curr Vasc Pharmacol; 2010 May; 8(3):301-26. PubMed ID: 19758115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.
    Robertson J; Peters MJ; McInnes IB; Sattar N
    Nat Rev Rheumatol; 2013 Sep; 9(9):513-23. PubMed ID: 23774906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis.
    Toms TE; Panoulas VF; Smith JP; Douglas KM; Metsios GS; Stavropoulos-Kalinoglou A; Kitas GD
    Ann Rheum Dis; 2011 Jun; 70(6):1025-32. PubMed ID: 21398331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
    Myasoedova E
    Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
    Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
    Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.
    Nurmohamed MT
    Vasc Health Risk Manag; 2007; 3(6):845-52. PubMed ID: 18200805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
    Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M
    Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
    Amezaga Urruela M; Suarez-Almazor ME
    Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.
    Semb AG; Ikdahl E; Wibetoe G; Crowson C; Rollefstad S
    Nat Rev Rheumatol; 2020 Jul; 16(7):361-379. PubMed ID: 32494054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
    Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
    Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipids in RA: Is Less Not Necessarily More?
    Plutzky J; Liao KP
    Curr Rheumatol Rep; 2018 Feb; 20(2):8. PubMed ID: 29464513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis.
    McCarey D; Sturrock RD
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S124-6. PubMed ID: 19822058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
    van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
    Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
    Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
    Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
    Venetsanopoulou AI; Pelechas E; Voulgari PV; Drosos AA
    Rheumatol Int; 2020 Aug; 40(8):1181-1191. PubMed ID: 32524301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.